For the quarter ended March 2024, Revvity (RVTY) reported revenue of $649.92 million, down 3.7% over the same period last year. EPS came in at $0.98, compared to $1.01 in the year-ago quarter.The reported revenue represents a surprise of +0.45% over the Zacks Consensus Estimate of $647.02 million. With the consensus EPS estimate being $0.94, the EPS surprise was +4.26%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

FOR IMMEDIATE RELEASE April 29, 2024 Revvity Announces Financial Results for the First Quarter of 2024 • Revenue of $650 million; (4)% reported growth; (3)% organic growth • First quarter GAAP EPS of $0.21; Adjusted EPS from continuing operations of $0.98 • Reaffirms full year 2024 organic growth and adjusted EPS guidance WALTHAM, Mass. -- Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024. The Company reported GAAP earnings per share of $0.21, as compare ...

Revvity (RVTY) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.26%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.15 per share when it actually produced earnings of $1.25, delivering a surprise of 8.70%.Over the last four quarters ...

Revvity, Inc. (RVTY) recently announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with its T-SPOT.TB test. The solution, which has an intuitive software user interface, is expected to simplify lab workflows.The latest product is expected to significantly boost Revvity’s Diagnostics segment and solidify its foothold in the infectious diseases space.Significance of the LaunchPer Revvity, the easy-to-use Auto-Pure 2400 platform has been designed to provide efficient workflows in the ...

Revvity, Inc. (RVTY) recently announced that its software and informatics division, Revvity Signals, will launch Signals Synergy. Per the company, it is a software solution designed to drive greater collaboration, project management and data exchange between pharmaceutical and biotechnology sponsors with their external contract partners.Revvity is expected to officially introduce Signals Synergy at the ongoing Bio-IT World Conference & Expo in Boston, MA.The latest product is expected to significantly boost ...

Revvity (RVTY) shares rallied 4.1% in the last trading session to close at $110.72. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.6% loss over the past four weeks.The prices are likely to have moved higher in anticipation of positive first quarter results, scheduled to be announced on Apr 29.This maker of scientific instruments is expected to post quarterly earnings of $0.94 per share in its upcoming repo ...

Revvity, Inc. (RVTY) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by its fourth-quarter 2023 and its focus on artificial intelligence (AI) also looks promising. Headwinds resulting from foreign exchange volatility and integration risks are major downsides.Over the past year, this Zacks Rank #3 (Hold) stock has lost 21.2% against the 6% rise of the industry and 27.7% growth of the S&P 500.The renowned provider of health science solutions has a m ...

Revvity, Inc. (RVTY) recently introduced the new Signals ChemDraw offering through its software and informatics division, Revvity Signals Software. The innovative chemistry suite is expected to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, and academia develop and communicate complex chemical concepts and collaborate across disciplines.The latest product is expected to significantly boost Revvity’s Signals Software portfolio on a global scale and solidify it ...

Revvity, Inc. (RVTY) recently announced the introduction of a flexible end-to-end workflow solution for newborn research. This will likely enable the users to utilize different instruments, reagents and databases based on a lab’s requirements.The research-use-only offering includes dried blood spot collection and processing devices, Chemagic kits and instruments for nucleic acid extraction, liquid handlers and reagents for library preparation, VICTOR2 D Instrument for sample quality control and software cap ...

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, the latest advancement in the Revvity Signals Software portfolio. This innovative chemistry suite is set to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, as well as academia, develop and communicate complex chemical concepts and collaborate across disciplines. ...